Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Lineage Commitment

Lineage Commitment

Commitment is the process whereby stem cells:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026

Same author

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

The New England journal of medicine·2026

Same author

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Blood·2026

Same author

Defining a role for venetoclax and hypomethylating agent therapy in younger adults with acute myeloid leukemia.

Cancer·2026

Same author

Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Leukemia & lymphoma·2026

Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 21, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Chronic myelogenous leukemia, version 1.2015.

Susan O'Brien, Jerald P Radich, Camille N Abboud

Journal of the National Comprehensive Cancer Network : JNCCN

|November 2, 2014

Summary

This summary is machine-generated.

Chronic myelogenous leukemia (CML) management in advanced phases involves tyrosine kinase inhibitors (TKIs) and chemotherapy. Allogeneic stem cell transplant offers a cure, with TKIs bridging to this procedure.

More Related Videos

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Related Experiment Videos

Last Updated: Apr 21, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Area of Science:

Hematology
Oncology

Background:

Chronic myelogenous leukemia (CML) typically presents in the chronic phase.
Untreated CML progresses to advanced phases: accelerated or blast phase.
Advanced phase CML requires specific therapeutic strategies.

Purpose of the Study:

To outline the NCCN Guidelines for diagnosing and managing advanced phase CML.
To review the efficacy of tyrosine kinase inhibitors (TKIs) in advanced CML.
To discuss the role of allogeneic hematopoietic stem cell transplant in CML treatment.

Main Methods:

Review of current NCCN Guidelines for CML management.
Analysis of treatment outcomes with TKIs in accelerated and blast phase CML.
Evaluation of TKI use as a bridge to allogeneic stem cell transplant.

Main Results:

TKIs demonstrate favorable response rates in accelerated and blast phase CML.
Combination therapy with TKIs and chemotherapy improves outcomes in blast phase CML.
TKIs are beneficial as a bridge to allogeneic stem cell transplant for advanced CML.

Conclusions:

NCCN Guidelines provide a framework for advanced CML diagnosis and management.
TKIs are crucial in managing advanced CML, both as monotherapy and in combination.
Allogeneic stem cell transplant remains a curative option, often facilitated by TKI treatment.